Related Experiment Video
Updated: Jul 24, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Warfarin for ischemic heart disease
1Heartcenter, 540 Department of Cardiology, P.O. Box 9101, University Medical Center St Radboud, Nijmegen, The Netherlands.
Insights
Oral anticoagulation effectively prevents recurrent ischemic events after myocardial infarction, outperforming placebo. However, aspirin is preferred due to similar efficacy and reduced bleeding risk compared to oral anticoagulants.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Oral anticoagulants were historically used for secondary ischemic heart disease prevention.
- The advent of aspirin, particularly low-dose aspirin, reduced interest in oral anticoagulants due to bleeding risks.
Purpose of the Study:
- To review the efficacy and safety of oral anticoagulation for ischemic heart disease.
- To compare oral anticoagulation with placebo and low-dose aspirin.
- To evaluate combination therapy of oral anticoagulants and aspirin versus aspirin alone.
Main Methods:
- Review of existing literature on oral anticoagulation and aspirin in ischemic heart disease.
- Comparison of outcomes including recurrent ischemic events and major bleeding.
- Analysis of specific scenarios: post-myocardial infarction, coronary angioplasty, and post-coronary surgery.
Main Results:
- Oral anticoagulation significantly reduces recurrent ischemic events post-myocardial infarction compared to placebo, with a major bleeding risk of 1 per 100 patient-years.
- After myocardial infarction, oral anticoagulation shows similar efficacy to aspirin but with comparable excess bleeding, making aspirin preferable.
- Combination therapy with oral anticoagulants and aspirin is superior to aspirin alone for preventing recurrent events if the international normalized ratio is maintained above 2.0, despite a similar bleeding risk.
- Warfarin before coronary angioplasty shows promise, but not after intervention.
- Long-term oral anticoagulation did not improve graft patency post-coronary surgery but improved survival in one trial.
Conclusions:
- Aspirin is generally preferred over oral anticoagulation for secondary prevention post-myocardial infarction due to a better safety profile.
- Combination therapy warrants consideration for specific high-risk patients undergoing interventions, balancing efficacy against bleeding risk.
- The role of oral anticoagulation in specific cardiovascular interventions and surgeries requires further nuanced evaluation.
Abstract:
Oral anticoagulation is one of the oldest ways for preventing secondary ischemic heart disease. With the introduction of aspirin, and low-dose aspirin in particular, the interest in oral anticoagulants has diminished, given the inherent bleeding risk. This short review deals with the efficacy and safety of oral anticoagulation in treating ischemic heart disease compared to placebo and to low-dose aspirin. Also, the comparison of the combination of oral anticoagulants and aspirin to aspirin alone is made. After myocardial infarction, oral anticoagulation is far superior to placebo in preventing recurrent ischemic events, with a risk of major bleeding of 1 per 100 patient-years. Oral anticoagulation seems equivalent to aspirin after myocardial infarction, but shows the same excess bleeding. Clearly, aspirin is, therefore, preferable for this indication. Combination therapy with oral anticoagulants and aspirin seems superior to aspirin alone provided the international normalized ratio is kept over 2.0. Also, here bleeding occurs in 1 out of 100 patient-years and the risk must be weighed against the risk of recurrent ischemic events. In coronary angioplasty, warfarin given before intervention looks promising in one large trial, but when given after intervention it is not beneficial and leads to more bleeding. Long-term oral anticoagulation does not lead to better graft patency after coronary surgery, but in one large trial it did lead to a better rate of survival.
More Related Videos
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:26Coronary Artery Disease IV: Preventive Measures
01:29Venous Thrombosis III: Interprofessional Care